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etronidazole vaginal gel 0.75% (MetroGel-
Vaginal(R), 3M Pharmaceuticals, St. Paul, MN)
is the intravaginal form of the antibacterial, anti-
protozoal agent metronidazole. MetroGel-Vaginal
is indicated for the treatment of bacterial vaginosis
(BV) and has been shown to be as effective as the
oral form of metronidazole for this condition. Re-
cently, a single daily five-day dosing regimen was
approved by the Food and Drug Administration. z
The prior dosing regimen was twice daily for five
days.The current product labeling allows for either
dosing regimen to be used.
STRUCTURE AND DERIVATION
Metronidazole is a nitroimidazole derivative. Its
chemical name is 2-methyl-5-nitroimidazole-1-
ethanol. Metronidazole vaginal gel 0.75% is admin-
istered as a single 5-g dose via intravaginal appli-
cator. Each gram of MetroGel-Vaginal contains 7.5
mg of metronidazole in a gelled, purified water so-
lution, containing 0.8 mg of methylparaben, 0.2 mg
of propylparaben, propylene glycol, carbomer 934p,
sodium hydroxide (to adjust pH), and edetate di-
sodium. The gel is formulated at pH 4.0 (normal
vaginal pH) and is free of mineral oil. Each appli-
catorful delivers 5 g of gel, containing approxi-
mately 37.5 mg of metronidazole.
MECHANISM OF ACTION
Metronidazole is a small uncharged molecule that
exerts its biologic activity through reduction of its
nitro group.
3 Anaerobic or microaerophilic condi-
tions promote activation of metronidazole.4 The
action of metronidazole is believed to consist of
three successive steps:s entry of the drug into tar-
get cells, activation by a reduction process, and
toxic effects of the reduced product. The reduction
of the nitro group of the 5-nitroimidazole results in
the formation of toxic derivatives, which kill sus-
ceptible bacteria by interacting with DNA.4,5 The
reduction of metronidazole in anaerobic organisms
most likely occurs in a one-electron step and is
assumed to lead first to the formation of a free
radical anion.4,5
The proposed site of metronidazole reduction is
the pyruvate phosphoroclastic reaction in which
feredoxin serves as the terminal electron accep-
tor.4,s This process, and thus the level of antimi-
crobial activity, is markedly influenced by the oxy-
gen tension of the environment.4
PHARMACOKINETICS
The bioavailability of metronidazole varies accord-
ing to the route of administration.6 Intravenous or
oral administration of metronidazole results in
nearly 100% bioavailability, and the drug diffuses
readily to nearly all body tissues. 7 Topical admin-
istration (rectal or intravaginal) reduces the bio-
availability, resulting in lower serum concentra-
tions of the drug. 7,8 Metronidazole is metabolized
by the liver into acid and hydroxy metabolites.9
The hydroxy metabolite is present in plasma in
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Fig. I. Mean serum concentrations of metronidazole over time following a single 5-g intravaginal dose of 0.75% metroni-
dazole gel or a single 500-mg oral dose of metronidazole in 12 normal, healthy volunteers. MetroGeI-Vaginal produces only
2% of the mean peak serum concentration of a standard oral metronidazole dose.
considerable amounts after oral administration.3
Metronidazole is excreted primarily in the urine as
parent drug, oxidative metabolites and conjugates.
The half life of metronidazole in plasma and tis-
sues is 8 hours.1
The pharmacokinetic characteristics of metroni-
dazole vaginal gel 0.75% were investigated in 12
healthy adult volunteers. 11 A single 5-g dose of gel
(37.5 mg of metronidazole) was compared with a
single 500-mg dose of oral metronidazole. Results
of the study demonstrated a mean maximum serum
concentration of 237 ng/ml following a single 5-g
dose of metronidazole vaginal gel 0.75% (range:
152-368 ng/ml). A mean maximum serum concen-
tration of 12,785 ng/ml was achieved following a
single 500-mg oral dose of metronidazole (range:
10,013-17,400 ng/ml) (Fig. 1). These peak concen-
trations were achieved 6-12 hours after the gel was
used and 1-2 hours after the oral metronidazole
was taken. Therefore, the mean peak metronida-
zole serum concentration following intravaginal ad-
ministration of a single 5-g dose of gel is less than
2% of that seen following a single 500-mg oral dose
of metronidazole. Metronidazole vaginal gel 0.75%
is approximately 56% bioavailable, relative to oral
metronidazole. However, since only 37.5 mg of
metronidazole is delivered in each 5-g dose of gel,
total systemic exposure to the drug is dramatically
reduced compared with standard doses of oral met-
ronidazole.
A second pharmacokinetic study of metronida-
zole vaginal gel 0.75% was conducted in patients
with BV. lz The five-day, twice-daily therapeutic
regimen was evaluated. The objectives of the
study were to determine the amount of drug ab-
sorbed and the mean maximum serum concentra-
tion achieved relative to normal, healthy volunteers
(dose 1) and to determine the multiple dose phar-
macokinetics (steady state) in this group of patients
(dose 9). Vaginal absorption of the metronidazole
gel formulation in patients with BV was similar to
that seen in normal, healthy volunteers.
Following single and multiple 5-g doses of met-
ronidazole 0.75% vaginal gel (twice-daily dose) in
patients with BV, a mean maximum serum concen-
tration of 214 ng/ml on day and 294 ng/ml on day
9 were reported. Similar steady-state serum con-
centrations were noted after the first dose and fol-
lowing a full therapeutic course of metronidazole
vaginal gel 0.75% in patients with BV. Results from
both studies show that minimal concentrations of
metronidazole are detected in the systemic circu-
lation after single- and multiple-dose administra-
tion of intravaginal metronidazole gel administra-
tion in normal, healthy volunteers and in patients
with BV, respectively. Metronidazole vaginal gel
0.75% produces only 2% of the mean peak serum
concentrations of a standard oral metronidazole
dose, with a 96% reduction in total systemic expo-
sure.
SIDE EFFECTS AND INTERACTIONS
Metronidazole vaginal gel 0.75% is associated with
a low incidence of adverse effects and is well tol-
erated. Safety data for the intravaginal administra-
tion of the drug was obtained from a total of 800
patients who received the drug in controlled clini-
cal trials. Less than 1% of patients discontinued
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therapy due to side effects. The most frequently
reported side effects were related to the genital
tract, including vaginal discharge (12%), symptom-
atic candidiasis (6-10%), and vulvovaginal irritation
(9%). Gastrointestinal side effects, commonly re-
ported following oral metronidazole therapy, were
minimal with intravaginal metronidazole gel (nau-
sea, 2-4%; metallic taste, 1.7-2%). z
In a randomized, single-blind controlled trial of
metronidazole vaginal gel 0.75% vs. oral metroni-
dazole, the incidence and severity of gastrointesti-
nal adverse events reported by subjects who re-
ceived the intravaginal gel was lower than those
reported by subjects who received oral metronida-
zole (P 0.014). This is likely due to the minimal
systemic exposure metronidazole vaginal gel 0.75%
produces relative to oral metronidazole. The prod-
uct is contraindicated in patients with a prior his-
tory of hypersensitivity to metronidazole, parabens,
or other ingredients of the formulation. Oral met-
ronidazole has been reported to potentiate the an-
ticoagulant effect of warfarin and other coumarin
anticoagulants, resulting in a prolongation of pro-
thrombin time. 13 This possible drug interaction
should be considered when metronidazole vaginal
gel 0.75% is prescribed for patients on this type of
anticoagulant therapy.
SPECTRUM OF ANTIMICROBIAL ACTIVITY
Metronidazole is a widely used antimicrobial agent
that is active against both anaerobic bacteria and
protozoa.
14 Unlike other imidazole derivatives, the
drug does not possess any antifungal activity. Met-
ronidazole is active in vitro against most obligate
anaerobes but does not possess any clinically rel-
evant activity against facultative anaerobes or aer-
obes at concentrations achievable with systemic
therapy. Against susceptible organisms, metronida-
zole is generally bactericidal at concentrations
equal to or slightly higher than the minimum in-
hibitory concentration. Metronidazole has been
shown to have in vitro and clinical activity against
the following organisms:
Anaerobic gram-negative bacilli: Bacteroides spe-
cies, including the Bacteroides fragilis group; Pre-
votella species; Fusobacterium
Anaerobic gram-positive bacilli: Clostridium spe-
cies, Eubacterium species
Anaerobic gram-positive cocci: Peptostreptococcus
species
Protozoa: Trichomonas vaginalis, Entamoeba histo-
lytica
Clinically, metronidazole vaginal gel 0.75% has
been shown to decrease the rate of isolation of the
BV pathogens Gardnerella vaginalis, Bacteroides spe-
cies, and Mycoplasma hominis.s Increases in vaginal
lactobacilli were observed in BV patients following
therapy. Metronidazole vaginal gel 0.75% is formu-
lated at a concentration of 7,500 pg/ml of metroni-
dazole, thus high intravaginal concentrations of
metronidazole (higher than those achievable with
systemic therapy) can be expected during intra-
vaginal therapy.
CLINICAL APPLICATIONS
Metronidazole vaginal gel 0.75% is indicated for
the treatment of BV. A total of five controlled clini-
cal studies evaluating the efficacy of metronidazole
vaginal gel 0.75% have been conducted. ’s-18
These trials included the following study designs:
1) a randomized, single-blind controlled trial of
metronidazole vaginal gel 0.75% daily vs. twice-
daily dosing; 2) a randomized, single-blind con-
trolled trial of metronidazole vaginal gel 0.75%
(twice-daily dosing regimen) vs. 500 mg of oral
metronidazole twice daily for 7 days; 3) Two ran-
domized, double-blind, placebo-controlled trials of
metronidazole vaginal gel 0.75% (twice-daily dos-
ing); 4) a randomized, double-blind, controlled trail
of metronidazole vaginal gel 0.75% (twice-daily
dosing) vs. triple sulfa cream.
A total of514 patients were enrolled in the study
comparing daily vs. twice daily dosing of metroni-
dazole vaginal gel 0.75%:8 252 were randomized to
the once-a-day dose (at bedtime) for 5 days, and
262 were randomized to the twice-a-day dose
(morning and evening) for 5 days. Once- and twice-
daily dosing regimens of the gel were equally ef-
fective in eradicating BV at both the first return
visit (12-17 days after initiation of therapy) and the
final return visit (one month after therapy). Clinical
cure rates based on patients considered evaluable
at the first return visit were 77% and 80% for daily
and twice-daily dosing regimens, respectively.
Rates of recurrence were also very similar for the
two treatment regimens. Of patients deemed cured
at the first return visit, 73% and 74% of the patients
in the daily and twice-daily treatment groups, re-
spectively, remained cured at the final return visit.
In a study comparing oral metronidazole to met-
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ronidazole vaginal gel 0.75%, a total of 112 pa-
tients were enrolled; 56 were randomized to re-
ceive intravaginal therapy twice a day for 5 days,
and 56 were randomized to receive 500 mg of oral
metronidazole twice a day for 7 days. Metronida-
zole vaginal gel 0.75% and oral metronidazole were
equally effective in curing BV at both the first re-
turn visit (11-17 days after initiation of therapy)
and the final visit (one month following therapy).
Cure rates of 84% and 85% were noted at the first
return visit for patients treated with intravaginal
and oral metronidazole, respectively. At the final
visit, 71% of patients in each treatment arm were
considered cured. Microbiologic efficacy, as as-
sessed by Gram stain, was consistent with clinical
findings. At first return visit, 84% of intravaginally
treated patients and 85% of orally treated patients
were considered cured. Recurrence rates were also
similar for both treatment groups. In the intravagi-
nally treated group, 79% of the patients deemed
cured at the first return visit remained cured at the
final visit, compared with 78% of patients treated
with oral metronidazole.
Patients with BV were enrolled in two double-
blind multicenter studies of metronidazole vaginal
gel 0.75% (twice-daily dosing) vs. placebo gel. ls,16
A total of 87 patients were enrolled in the first
study: 45 patients were randomized to intravaginal
metronidazole and 42 to placebo. A total of 69 pa-
tients were enrolled in the second study: 41 pa-
tients to intravaginal metronidazole and 28 to pla-
cebo. In both trials, metronidazole vaginal gel
0.75% and placebo gel were given twice a day for
five days. In both placebo-controlled trials, metro-
nidazole vaginal gel 0.75% was shown to be supe-
rior to placebo gel at both the first return visit and
final return visits. In the first study,
is cure rates at
the first return visit (17-21 days after initiation of
therapy) were 81% for intravaginal metronidazole
and 11% for placebo. Clinical cure rates at the final
return visit (one month after therapy) were 76% for
intravaginal metronidazole and 6% for placebo.
Comparable findings were noted with the second
study.
16 Clinical cure rates at the first return visit
(9-12 days after initiation of therapy) were 82% for
intravaginal metronidazole and 39% for placebo.
Cure rates at the final return visit (one month after
therapy) were 69% for intravaginal metronidazole
and 13% for placebo. These differences were all
statistically significant. Recurrence was low in both
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Table I. Costs of selected antibiotics for the
treatment of bacterial vaginosis
Drug Dosage
Average wholesale
prices for a full
course of therapy
Cleocin vaginal cream applicatorful $35.36
daily for 7 days
Cleocin capsules 300 mg twice $38.92
daily for 7 days
Flagyl tablets 500 mg twice $37.81
daily for 7 days
Flagyl ER tablets 750 mg daily $39.90
for 7 days
Generic metronidazole 500 mg twice $5.25
daily for 7 days
MetroGeI-Vaginal (R) applicatorful $30.48
once or twice
daily for 5 days
aFrom First Data Bank: Price Alert. San Bruno, CA: Hearst Corporation,
April 1998.
trials. Of the patients treated with metronidazole
vaginal gel 0.75% who were considered cured at
the first return visit, 97% and 85% remained cured
at the final visit in studies one is and two,
16 respec-
tively.
Finally, 247 patients were enrolled in a trial
comparing metronidazole vaginal gel 0.75% to
triple sulfa cream. 17 A total of 124 patients were
randomized to receive intravaginal metronidazole
and 123 were randomized to receive triple sulfa
cream. Both therapies were administered twice a
day for five days. At the first return visit (17-21
days after initiation of therapy), 79% of patients
treated with intravaginal metronidazole and 71% of
patients treated with triple sulfa cream were con-
sidered cured. At the final return visit (one month
after therapy), 66% of patients treated with metro-
nidazole vaginal gel 0.75% and only 47% of pa-
tients treated with triple sulfa cream were consid-
ered cured. The difference at the final return visit
was statistically significant (P < 0.02). The superior
efficacy of metronidazole vaginal gel 0.75% at the
final return visit is consistent with the fact that
certain BV pathogens, including Gardnerella vagi-
nalis and anaerobic gram-negative rods, are not
highly sensitive to triple sulfa cream. 17
COST
Table presents the comparative average whole-
sale prices to pharmacists for a course of therapy of
select antibiotics used in the treatment of BV.
These drugs represent the accepted forms and dos-METROGEL-VAGINAL WAIN
ing regimens of effective therapy for the treatment
of BV.9 With the exception of generic metronida-
zole tablets, metronidazole vaginal gel 0.75% is the
least expensive of the therapies for BV.
CONCLUSION
There are multiple methods for treating BV. Met-
ronidazole vaginal gel 0.75% is an important option,
for it has many advantages over other standard
therapies. The advantages of this treatment modal-
ity include equal efficacy compared to oral admin-
istration, minimal side-effect profile as a result of
low serum levels, and a short five-day single dosing
regimen which is now approved by the Food and
Drug Administration.
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